Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Corren

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Current Medical Research and Opinion|October 24, 2017
Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trialsJonathan Corren, Abhishek Kavati, Benjamin Ortiz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 14, 2004
Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesisJonathan Corren, David Diaz-Sanchez, Andrew Saxon, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 14, 2021
A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumabJonathan Corren, Jared Silver, Nestor A Molfino, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 6, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial AllergyJonathan Corren, Christopher S Ambrose, Kinga Sałapa, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2020
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAYJonathan Corren, Esther Garcia Gil, Janet M Griffiths, et al.
The New England Journal of Medicine|September 7, 2017
Tezepelumab in Adults with Uncontrolled AsthmaJonathan Corren, Jane R Parnes, Liangwei Wang, et al.
Immunotherapy|January 9, 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, et al.
The Journal of Allergy and Clinical Immunology|August 12, 2008
A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjectsKenneth Tripp, William K McVicar, Parameswaran Nair, et al.
Allergy|December 16, 2021
Baseline type 2 biomarker levels and response to tezepelumab in severe asthmaJonathan Corren, Tuyet-Hang Pham, Esther Garcia Gil, et al.
Allergy and Asthma Proceedings|June 21, 2017
Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature reviewJonathan Corren, Abhishek Kavati, Benjamin Ortiz, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Current Medical Research and Opinion|October 24, 2017
Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trialsJonathan Corren, Abhishek Kavati, Benjamin Ortiz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 14, 2004
Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesisJonathan Corren, David Diaz-Sanchez, Andrew Saxon, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 14, 2021
A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumabJonathan Corren, Jared Silver, Nestor A Molfino, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 6, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial AllergyJonathan Corren, Christopher S Ambrose, Kinga Sałapa, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2020
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAYJonathan Corren, Esther Garcia Gil, Janet M Griffiths, et al.
The New England Journal of Medicine|September 7, 2017
Tezepelumab in Adults with Uncontrolled AsthmaJonathan Corren, Jane R Parnes, Liangwei Wang, et al.
Immunotherapy|January 9, 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, et al.
The Journal of Allergy and Clinical Immunology|August 12, 2008
A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjectsKenneth Tripp, William K McVicar, Parameswaran Nair, et al.
Allergy|December 16, 2021
Baseline type 2 biomarker levels and response to tezepelumab in severe asthmaJonathan Corren, Tuyet-Hang Pham, Esther Garcia Gil, et al.
Allergy and Asthma Proceedings|June 21, 2017
Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature reviewJonathan Corren, Abhishek Kavati, Benjamin Ortiz, et al.
Pageof 15